Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tepotinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Japan’s MHLW Approves AmoyDx PCR Panel As TEPMETKO CDx
Details : Tepmetko (tepotinib) is a kinase inhibitor indicated for the treatment of adult patients with mNSCLC harboring mesenchymal epithelial transition (MET) exon 14 skipping alterations.
Product Name : Tepmetko
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 17, 2021
Lead Product(s) : Tepotinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
